Bone Mineral Density Is a Predictor of Mortality in Female Patients with Cholangiocellular Carcinoma Undergoing Palliative Treatment.
CCA
cholangiocellular carcinoma
osteopenia
prognostic marker
survival
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
11 Jul 2022
11 Jul 2022
Historique:
received:
18
05
2022
revised:
05
07
2022
accepted:
07
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Cholangiocellular adenocarcinoma (CCA) is a rare and aggressive malignancy originating from the bile ducts. Its general prognosis is poor as therapeutic options are limited. Many patients present with advanced stages of disease, and palliative chemotherapy remains the only treatment option. Prognostic markers to assess the outcome of chemotherapeutic treatment in CCA are limited. We therefore evaluated bone mineral density (BMD) as a prognostic tool in patients with advanced CCA. We included 75 patients with advanced CCA that were treated at our academic tumor center. Prior to treatment, bone mineral density was analyzed at the first lumbar vertebra using routine CT scans in the venous phase and the local PACS (IntelliSpace PACS, Philips, Amsterdam, The Netherlands). BMD was not significantly different between male and female patients but decreased with age. Patients with BMD above 167 HU have a significantly improved overall survival (474 days vs. 254 days; log-rank X Our data suggest that BMD is a valuable, easily accessible, and independent prognostic marker for overall survival in patients with advanced CCA. Furthermore, subgroup analysis showed the sex specificity of this marker, which demonstrated relevance only in female patients.
Sections du résumé
BACKGROUND
BACKGROUND
Cholangiocellular adenocarcinoma (CCA) is a rare and aggressive malignancy originating from the bile ducts. Its general prognosis is poor as therapeutic options are limited. Many patients present with advanced stages of disease, and palliative chemotherapy remains the only treatment option. Prognostic markers to assess the outcome of chemotherapeutic treatment in CCA are limited. We therefore evaluated bone mineral density (BMD) as a prognostic tool in patients with advanced CCA.
PATIENTS AND METHODS
METHODS
We included 75 patients with advanced CCA that were treated at our academic tumor center. Prior to treatment, bone mineral density was analyzed at the first lumbar vertebra using routine CT scans in the venous phase and the local PACS (IntelliSpace PACS, Philips, Amsterdam, The Netherlands).
RESULTS
RESULTS
BMD was not significantly different between male and female patients but decreased with age. Patients with BMD above 167 HU have a significantly improved overall survival (474 days vs. 254 days; log-rank X
CONCLUSIONS
CONCLUSIONS
Our data suggest that BMD is a valuable, easily accessible, and independent prognostic marker for overall survival in patients with advanced CCA. Furthermore, subgroup analysis showed the sex specificity of this marker, which demonstrated relevance only in female patients.
Identifiants
pubmed: 35884968
pii: biomedicines10071660
doi: 10.3390/biomedicines10071660
pmc: PMC9313370
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Cancer Aid
ID : 57584079
Organisme : European Research Council
ID : 771083
Pays : International
Références
Front Immunol. 2020 Jun 30;11:1387
pubmed: 32695120
Am J Clin Nutr. 2004 Aug;80(2):496-503
pubmed: 15277176
Liver Transpl. 2016 Aug;22(8):1092-8
pubmed: 27064263
Pflugers Arch. 2017 Jun;469(5-6):573-591
pubmed: 28101649
J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
pubmed: 11158037
BMJ. 1996 May 18;312(7041):1254-9
pubmed: 8634613
Oncogene. 2015 Jul;34(27):3493-503
pubmed: 25174402
J Bone Miner Res. 2005 Nov;20(11):1912-20
pubmed: 16234963
BMC Cancer. 2002 Sep 12;2(1):22
pubmed: 12377099
Bone. 2003 Mar;32(3):211-6
pubmed: 12667548
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
J Clin Endocrinol Metab. 2008 Mar;93(3):861-8
pubmed: 18160467
Nature. 2006 Mar 30;440(7084):692-6
pubmed: 16572175
Breast. 2001 Aug;10(4):313-7
pubmed: 14965600
J Clin Invest. 2016 Mar 1;126(3):1114-25
pubmed: 26901812
J Clin Med. 2021 Aug 23;10(16):
pubmed: 34442036
J Clin Med. 2021 Mar 25;10(7):
pubmed: 33806224
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Maturitas. 2010 Apr;65(4):348-51
pubmed: 20079983
PLoS One. 2012;7(12):e51862
pubmed: 23251644
J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74
pubmed: 9661593
J Bone Joint Surg Am. 2011 Jun 1;93(11):1057-63
pubmed: 21655899
J Hepatol. 2020 Feb;72(2):353-363
pubmed: 31954497
J Clin Invest. 1969 Dec;48(12):2191-201
pubmed: 5355335
J Clin Med. 2021 Sep 23;10(19):
pubmed: 34640358
N Engl J Med. 1997 Feb 27;336(9):611-7
pubmed: 9032046
Am J Epidemiol. 1986 Nov;124(5):752-61
pubmed: 3766508
Epidemiol Rev. 1993;15(1):48-65
pubmed: 8405212
Ann Intern Med. 2013 Apr 16;158(8):588-95
pubmed: 23588747
Curr Opin Support Palliat Care. 2018 Dec;12(4):394-403
pubmed: 30102621